HK1249103B - 多環氨甲醯基吡啶酮化合物及其藥物用途 - Google Patents
多環氨甲醯基吡啶酮化合物及其藥物用途Info
- Publication number
- HK1249103B HK1249103B HK18108873.5A HK18108873A HK1249103B HK 1249103 B HK1249103 B HK 1249103B HK 18108873 A HK18108873 A HK 18108873A HK 1249103 B HK1249103 B HK 1249103B
- Authority
- HK
- Hong Kong
- Prior art keywords
- polycyclic
- pharmaceutical use
- carbamoylpyridone compounds
- carbamoylpyridone
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142338P | 2015-04-02 | 2015-04-02 | |
| PCT/US2016/025740 WO2016161382A1 (en) | 2015-04-02 | 2016-04-01 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1249103B true HK1249103B (zh) | 2020-02-07 |
Family
ID=55754453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18108247.4A HK1248688A1 (zh) | 2015-04-02 | 2018-06-27 | 多環氨甲醯基吡啶酮化合物及其藥物用途 |
| HK18108873.5A HK1249103B (zh) | 2015-04-02 | 2018-07-09 | 多環氨甲醯基吡啶酮化合物及其藥物用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18108247.4A HK1248688A1 (zh) | 2015-04-02 | 2018-06-27 | 多環氨甲醯基吡啶酮化合物及其藥物用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9630978B2 (zh) |
| EP (3) | EP3736274A1 (zh) |
| JP (2) | JP6402259B2 (zh) |
| KR (2) | KR20190057158A (zh) |
| CN (2) | CN110790773A (zh) |
| AU (3) | AU2016244035B2 (zh) |
| BR (1) | BR112017020837A2 (zh) |
| CA (1) | CA2980362C (zh) |
| EA (1) | EA201791872A1 (zh) |
| ES (2) | ES2837383T3 (zh) |
| HK (2) | HK1248688A1 (zh) |
| IL (1) | IL254552A0 (zh) |
| MX (1) | MX2017012393A (zh) |
| NZ (1) | NZ735575A (zh) |
| PL (1) | PL3277691T3 (zh) |
| PT (2) | PT3466490T (zh) |
| SG (1) | SG11201707905WA (zh) |
| SI (2) | SI3277691T1 (zh) |
| TR (1) | TR201905009T4 (zh) |
| WO (1) | WO2016161382A1 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35213A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico |
| TWI738321B (zh) * | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
| NZ735575A (en) * | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| AU2019277547A1 (en) | 2018-05-31 | 2021-01-14 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| IL279051B1 (en) | 2018-05-31 | 2024-09-01 | Shionogi & Co | Consequences of polycyclic carbamoylpyridone |
| KR20210142711A (ko) | 2019-03-22 | 2021-11-25 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| TW202120510A (zh) * | 2019-11-13 | 2021-06-01 | 大陸商上海拓界生物醫藥科技有限公司 | 新型四環雜環化合物及其藥物用途 |
| JPWO2021107066A1 (zh) | 2019-11-28 | 2021-06-03 | ||
| JP7453399B2 (ja) | 2020-02-24 | 2024-03-19 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ感染症を治療するための四環式化合物及びその使用 |
| CN116390924A (zh) * | 2020-09-30 | 2023-07-04 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| CN114426540B (zh) * | 2020-10-29 | 2024-04-26 | 上海拓界生物医药科技有限公司 | 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用 |
| WO2022089562A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海拓界生物医药科技有限公司 | 抑制基因缺陷的hiv病毒的用途 |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| WO2000039086A1 (fr) | 1998-12-25 | 2000-07-06 | Shionogi & Co., Ltd. | Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih |
| WO2001095905A1 (en) | 2000-06-14 | 2001-12-20 | Shionogi & Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
| ATE550320T1 (de) | 2001-08-10 | 2012-04-15 | Shionogi & Co | Antivirales mittel |
| PL370355A1 (en) | 2001-10-03 | 2005-05-16 | Ucb, S.A. | Pyrrolidinone derivatives |
| RS51542B (sr) | 2001-10-26 | 2011-06-30 | Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. | N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| EP1549315A4 (en) | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
| EP1564210B9 (en) | 2002-11-20 | 2010-03-31 | Japan Tobacco Inc. | 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| KR20090053867A (ko) | 2003-01-14 | 2009-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
| WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| WO2005074513A2 (en) | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors |
| US7619086B2 (en) | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| EP1756114B1 (en) | 2004-05-07 | 2014-11-19 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| JP4629104B2 (ja) | 2004-05-21 | 2011-02-09 | 日本たばこ産業株式会社 | ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤 |
| ES2363160T3 (es) | 2004-07-27 | 2011-07-22 | Gilead Sciences, Inc. | Conjugados de fosfonato nucelosidico como agentes anti-vih. |
| EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
| WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| US7858788B2 (en) | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| EP2465580B1 (en) | 2005-04-28 | 2013-12-18 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| AR057023A1 (es) | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
| CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
| BRPI0617842A2 (pt) | 2005-10-27 | 2011-08-09 | Shionogi & Co | composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica |
| SG170795A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| US8420821B2 (en) | 2006-03-06 | 2013-04-16 | Japan Tobacco Inc. | Process for production of 4-oxoquinoline compound |
| KR101023635B1 (ko) | 2006-03-06 | 2011-03-22 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 제조 방법 |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100092427A1 (en) | 2006-07-19 | 2010-04-15 | The University Of Georgia Research Foundation | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy |
| AR063710A1 (es) | 2006-09-12 | 2009-02-11 | Gilead Sciences Inc | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. |
| EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
| PT2487163T (pt) | 2007-02-23 | 2016-11-21 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| AU2008270630B2 (en) | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| EA200971096A1 (ru) | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Терапевтические композиции и их применение |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| JP5586602B2 (ja) | 2008-07-25 | 2014-09-10 | ビーブ・ヘルスケア・カンパニー | 化合物 |
| ES2448766T3 (es) | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Profármacos de dolutegravir |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP2465858B1 (en) | 2008-07-25 | 2013-12-25 | VIIV Healthcare Company | Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative |
| AU2009325128B2 (en) | 2008-12-11 | 2015-01-29 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| ES2969969T3 (es) | 2010-01-27 | 2024-05-23 | Viiv Healthcare Co | Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH |
| WO2011105590A1 (ja) | 2010-02-26 | 2011-09-01 | 日本たばこ産業株式会社 | １，３，４，８－テトラヒドロ－２Ｈ－ピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用 |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| JP5984218B2 (ja) | 2010-07-02 | 2016-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体 |
| BR112013002461A2 (pt) | 2010-08-05 | 2016-05-24 | Shionogi & Co | método para produzir um composto, e, cristal de um composto |
| PL2620436T3 (pl) | 2010-09-24 | 2018-10-31 | Shionogi & Co., Ltd. | Prolek podstawionej policyklicznej pochodnej karbamoilopirydonowej |
| KR20140027295A (ko) | 2011-04-21 | 2014-03-06 | 길리애드 사이언시즈, 인코포레이티드 | 벤조티아졸 화합물 및 이들의 약학적 용도 |
| US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013038407A1 (en) | 2011-09-14 | 2013-03-21 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
| BR112014008896A2 (pt) | 2011-10-12 | 2017-04-18 | Shionogi & Co | derivado de piridona policíclico tendo atividade inibidora de integrase |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| WO2014018449A1 (en) | 2012-07-25 | 2014-01-30 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
| BR112015002275A2 (pt) | 2012-08-03 | 2017-07-04 | Gilead Sciences Inc | processos e intermediários para a preparação de inibidores da integrase |
| PE20151326A1 (es) | 2012-12-14 | 2015-10-12 | Glaxosmithkline Llc | Composiciones farmaceuticas que comprenden derivados de betulina |
| WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| UY35213A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico |
| US20160000721A1 (en) | 2012-12-21 | 2016-01-07 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| WO2014200880A1 (en) * | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| AU2014286993B2 (en) * | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| NO2865735T3 (zh) * | 2013-07-12 | 2018-07-21 | ||
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| US9861620B2 (en) | 2013-09-27 | 2018-01-09 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as HIV integrase inhibitors |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| TWI738321B (zh) * | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| NZ735575A (en) * | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2016
- 2016-04-01 NZ NZ735575A patent/NZ735575A/en not_active IP Right Cessation
- 2016-04-01 EP EP20167360.5A patent/EP3736274A1/en not_active Withdrawn
- 2016-04-01 KR KR1020197014269A patent/KR20190057158A/ko active Application Filing
- 2016-04-01 JP JP2017549768A patent/JP6402259B2/ja active Active
- 2016-04-01 EP EP16716776.6A patent/EP3277691B1/en active Active
- 2016-04-01 ES ES18207888T patent/ES2837383T3/es active Active
- 2016-04-01 SI SI201630216T patent/SI3277691T1/sl unknown
- 2016-04-01 CA CA2980362A patent/CA2980362C/en active Active
- 2016-04-01 WO PCT/US2016/025740 patent/WO2016161382A1/en active Application Filing
- 2016-04-01 EA EA201791872A patent/EA201791872A1/ru unknown
- 2016-04-01 PT PT182078881T patent/PT3466490T/pt unknown
- 2016-04-01 PT PT16716776T patent/PT3277691T/pt unknown
- 2016-04-01 CN CN201911067354.7A patent/CN110790773A/zh active Pending
- 2016-04-01 SI SI201630966T patent/SI3466490T1/sl unknown
- 2016-04-01 AU AU2016244035A patent/AU2016244035B2/en active Active
- 2016-04-01 TR TR2019/05009T patent/TR201905009T4/tr unknown
- 2016-04-01 US US15/089,342 patent/US9630978B2/en active Active
- 2016-04-01 PL PL16716776T patent/PL3277691T3/pl unknown
- 2016-04-01 BR BR112017020837-7A patent/BR112017020837A2/pt not_active IP Right Cessation
- 2016-04-01 CN CN201680025671.0A patent/CN107531727B/zh active Active
- 2016-04-01 ES ES16716776T patent/ES2718410T3/es active Active
- 2016-04-01 KR KR1020177031329A patent/KR101982431B1/ko active IP Right Grant
- 2016-04-01 SG SG11201707905WA patent/SG11201707905WA/en unknown
- 2016-04-01 EP EP18207888.1A patent/EP3466490B1/en active Active
- 2016-04-01 MX MX2017012393A patent/MX2017012393A/es unknown
-
2017
- 2017-09-18 IL IL254552A patent/IL254552A0/en unknown
-
2018
- 2018-06-27 HK HK18108247.4A patent/HK1248688A1/zh unknown
- 2018-07-09 HK HK18108873.5A patent/HK1249103B/zh unknown
- 2018-09-10 JP JP2018168811A patent/JP6745308B2/ja active Active
- 2018-09-27 AU AU2018236826A patent/AU2018236826B2/en active Active
-
2019
- 2019-12-17 AU AU2019283812A patent/AU2019283812A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249103B (zh) | 多環氨甲醯基吡啶酮化合物及其藥物用途 | |
| HK1244000B (zh) | 多環氨基甲酰吡啶酮化合物及其藥物用途 | |
| HK1247614A1 (zh) | 治療化合物及其用途 | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| HK1252026A1 (zh) | 藥物組合及其應用 | |
| HK1248697A1 (zh) | 治療化合物及其用途 | |
| ZA201802256B (en) | Compounds and therapeutic uses thereof | |
| ZA201703976B (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
| HK1245113A1 (zh) | 藥物組合物及其用途 | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| GB201517133D0 (en) | New pharmaceutical use | |
| GB201616767D0 (en) | New pharmaceutical use | |
| GB201517454D0 (en) | New pharmaceutical use | |
| GB201517132D0 (en) | New pharmaceutical use | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201508613D0 (en) | New pharmaceutical use | |
| GB201508611D0 (en) | New pharmaceutical use | |
| GB201507813D0 (en) | New pharmaceutical use | |
| GB201513318D0 (en) | Novel compounds and their use | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |